PMID- 37847573
OWN - NLM
STAT- MEDLINE
DCOM- 20240206
LR  - 20240206
IS  - 1935-3227 (Electronic)
IS  - 1932-0620 (Linking)
VI  - 18
IP  - 1
DP  - 2024 Jan-Feb 01
TI  - 48-hour Induction of Transdermal Buprenorphine to Extended-release Buprenorphine.
PG  - 82-85
LID - 10.1097/ADM.0000000000001231 [doi]
AB  - Buprenorphine extended-release (BUP-XR) provides sustained delivery of 
      buprenorphine to control withdrawal and craving symptoms in the form of a monthly 
      injectable and has been shown to improve health outcomes in patients with opioid 
      use disorder. It is recommended that patients are stabilized with a transmucosal 
      buprenorphine product, for at least 7 days per the product monograph; however, 
      clinically, this timeline may be expedited. We report a case of a hospitalized 
      patient with unregulated fentanyl use who underwent a successful transdermal 
      buprenorphine induction for 48 hours to initiate BUP-XR with minimal levels of 
      withdrawal and without precipitating opioid withdrawal. The approach described 
      could provide a practical, patient-centered, accelerated induction strategy that, 
      once independently validated, could considerably facilitate the use of BUP-XR.
CI  - Copyright (c) 2023 American Society of Addiction Medicine.
FAU - Azar, Pouya
AU  - Azar P
AD  - From the Integrated Psychiatry, Pain, and Addiction Service, Vancouver General 
      Hospital, Vancouver, British Columbia, Canada (PA, JSHW, NM, MJI); Department of 
      Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada 
      (PA, NM); Addictions and Concurrent Disorders Research Group, Department of 
      Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada 
      (JSHW, RMK); BC Mental Health & Substance Use Services, Provincial Health 
      Services Authority, British Columbia, Canada (NM); Substance Use Response and 
      Facilitation Service, BC Children's Hospital, Provincial Health Services 
      Authority, British Columbia, Canada (MJI); Pharmaceutical Sciences, Vancouver 
      General Hospital, Vancouver, British Columbia, Canada (NP); Faculty of 
      Pharmaceutical Sciences, University of British Columbia, Vancouver, British 
      Columbia, Canada (NP); British Columbia Centre for Excellence in HIV/AIDS, 
      Vancouver, British Columbia, Canada (AA, MH, RB, JSGM); Pharmacokinetics Modeling 
      and Simulation Laboratory, Faculty of Pharmaceutical Sciences, University of 
      British Columbia, Vancouver, British Columbia, Canada (ST, ARM); Department of 
      Family Practice, Faculty of Medicine, University of British Columbia, Vancouver, 
      British Columbia, Canada (MH); School of Population and Public Health, Faculty of 
      Medicine, University of British Columbia, Vancouver, British Columbia, Canada 
      (RB); and Department of Medicine, Faculty of Medicine, University of British 
      Columbia, Vancouver, British Columbia, Canada (JSGM).
FAU - Wong, James S H
AU  - Wong JSH
FAU - Mathew, Nickie
AU  - Mathew N
FAU - Ignaszewski, Martha J
AU  - Ignaszewski MJ
FAU - Partovi, Nilufar
AU  - Partovi N
FAU - Krausz, Reinhard M
AU  - Krausz RM
FAU - Ajidahun, Adedayo
AU  - Ajidahun A
FAU - Thotakura, Sahithi
AU  - Thotakura S
FAU - Harris, Marianne
AU  - Harris M
FAU - Barrios, Rolando
AU  - Barrios R
FAU - Montaner, Julio S G
AU  - Montaner JSG
FAU - Maharaj, Anil R
AU  - Maharaj AR
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20231017
PL  - Netherlands
TA  - J Addict Med
JT  - Journal of addiction medicine
JID - 101306759
RN  - 40D3SCR4GZ (Buprenorphine)
RN  - 0 (Narcotic Antagonists)
RN  - 0 (Delayed-Action Preparations)
RN  - UF599785JZ (Fentanyl)
RN  - 0 (Analgesics, Opioid)
RN  - 5S6W795CQM (Naltrexone)
SB  - IM
MH  - Humans
MH  - *Buprenorphine/therapeutic use
MH  - Narcotic Antagonists/therapeutic use
MH  - Delayed-Action Preparations/therapeutic use
MH  - *Opioid-Related Disorders/drug therapy
MH  - Fentanyl
MH  - Analgesics, Opioid/therapeutic use
MH  - Naltrexone/therapeutic use
COIS- Pouya Azar is a consultant on Indivior-led buprenorphine extended-release 
      studies, which are unrelated to this case report. The other authors report no 
      conflicts of interest.
EDAT- 2023/10/17 18:43
MHDA- 2024/02/06 06:42
CRDT- 2023/10/17 12:04
PHST- 2024/02/06 06:42 [medline]
PHST- 2023/10/17 18:43 [pubmed]
PHST- 2023/10/17 12:04 [entrez]
AID - 01271255-990000000-00237 [pii]
AID - 10.1097/ADM.0000000000001231 [doi]
PST - ppublish
SO  - J Addict Med. 2024 Jan-Feb 01;18(1):82-85. doi: 10.1097/ADM.0000000000001231. 
      Epub 2023 Oct 17.